Genzyme, technically falling short of job-creation goals set by Massachusetts in an incentives package, has repaid the state $6 million.
Spokesperson Erin Emlock says in an email the company created about 300 jobs last year. But when it sold its genetic testing business in September, the count fell below the requisite 200 positions.
Mass High Tech reports that the prompt payback was praised by the Massachusetts Life Sciences Center, which provided the package.
Meanwhile, Genzyme is working to complete a new plant in Framingham, west of Boston, expected to come on line later this year. It will be home to Cerezyme and Fabrazyme, the production of which is being transferred out of the company's Allston Landing facility per a consent decree with the FDA.
Genzyme announced last week that it will build an additional manufacturing plant in Geel, Belgium, for the production of Myozyme and Lumizyme for Pompe disease. A ceremony last week marked the start of construction.
The plant will have an 8,000-liter production capacity. Commercial approvals for the site are expected beginning late 2014.
- here's the article
- see the Geel announcement